Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab

被引：5

作者：

Blauvelt, Andrew ^{[1
]}

Pink, Andrew ^{[2
]}

Worm, Margitta ^{[3
]}

Langley, Richard G. B. ^{[4
]}

Elewski, Boni E. ^{[5
]}

Le Gjerum ^{[6
]}

Guttman-Yassky, Emma ^{[7
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Guys Hosp, St Johns Inst Dermatol, London, England

[3] Charite Univ Med Berlin, Div Allergy & Immunol, Dept Dermatol Venereol & Allergol, Berlin, Germany

[4] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada

[5] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL USA

[6] LEO Pharma, Ballerup, Denmark

[7] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY USA

来源：

JAMA DERMATOLOGY | 2022年 / 158卷 / 11期

关键词：

D O I：

10.1001/jamadermatol.2022.3488

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：1327 / 1330

页数：4

共 6 条

[1]

Donlan Alexandra N, 2021, medRxiv, DOI 10.1101/2020.06.18.20134353

[2] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

[3] Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis [J].

Merola, Joseph F. ;

Bagel, Jerry ;

Almgren, Peter ;

Ropke, Mads A. ;

Lophaven, Katja W. ;

Vest, Natacha Strange ;

Grewal, Parbeer .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) :71-78

[4] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial [J].

Silverberg, J. I. ;

Toth, D. ;

Bieber, T. ;

Alexis, A. F. ;

Elewski, B. E. ;

Pink, A. E. ;

Hijnen, D. ;

Jensen, T. N. ;

Bang, B. ;

Olsen, C. K. ;

Kurbasic, A. ;

Weidinger, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) :450-463

[5] COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab [J].

Ungar, Benjamin ;

Glickman, Jacob W. ;

Golant, Alexandra K. ;

Dubin, Celina ;

Marushchak, Olga ;

Gontzes, Alyssa ;

Mikhaylov, Daniela ;

Singer, Giselle K. ;

Baum, Danielle ;

Wei, Nancy ;

Sanin, Antonio ;

Gruenstein, Diana ;

Lebwohl, Mark G. ;

Pavel, Ana B. ;

Guttman-Yassky, Emma .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (01) :134-142

[6] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) [J].

Wollenberg, A. ;

Blauvelt, A. ;

Guttman-Yassky, E. ;

Worm, M. ;

Lynde, C. ;

Lacour, J. -P. ;

Spelman, L. ;

Katoh, N. ;

Saeki, H. ;

Poulin, Y. ;

Lesiak, A. ;

Kircik, L. ;

Cho, S. H. ;

Herranz, P. ;

Cork, M. J. ;

Peris, K. ;

Steffensen, L. A. ;

Bang, B. ;

Kuznetsova, A. ;

Jensen, T. N. ;

osterdal, M. L. ;

Simpson, E. L. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) :437-449

← 1 →